Salvianolic acid A tiny pills, and Salvianolic acid A capsule

A technology of salvianolic acid and pellets, which is applied in the field of medicine, can solve the problems of many adverse reactions, high irritation, and low purity, and achieve the effect of improving diastolic function, increasing myocardial contractility, and relaxing aortic smooth muscle

Inactive Publication Date: 2007-10-10
正宇(香港)国际有限公司
View PDF0 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] The purpose of the invention is to solve the problems of low purity, high i

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] Example 1 90mg salvianolic acid A pellets / capsules

[0033] Raw material list:

[0034] Inert core

[0035] Sucrose starch pellets, 30-35 mesh 135.25mg

[0036] Salvianolic acid layer A

[0037] Salvianolic acid A or its salt 99.24mg

[0038] Sucrose 25.33mg

[0039] Hypromellose 13.07mg

[0040] separation layer

[0041] Hypromellose 9.75mg

[0042] Sucrose 27.99mg

[0043] Talc, 500 mesh 50.21mg

[0044] Enteric layer

[0045] HPMCAS-LF 65.21mg

[0046] Triethyl citrate 13.14mg

[0047] Talc, 500 mesh 20.06mg

[0048] outermost layer

[0049] Coloring mixture white (HPMC+titanium dioxide) 40.92mg

[0050] HPMC 10.59mg

[0051] Talc Trace

[0052] Total 510.76mg

[0053] Add salvianolic acid A in the adhesive solution that contains sucrose and hydroxypropyl methylcellulose (HPMC), form sucrose content and be 6.4% (weight), HPMC content be 3.2% (weight) and salvianolic acid A content are 25% by weight suspension. The sus...

Embodiment 2

[0057] Example 2 50mg salvianolic acid A pellets / capsules

[0058] Raw material list:

[0059] Inert core

[0060] Sucrose-starch small sugar pills, 30-35 mesh 134.35mg

[0061] Salvianolic acid layer A

[0062] Salvianolic acid A 54.89mg

[0063] Sucrose 25.41mg

[0064] Hypromellose 13.01mg

[0065] separation layer

[0066]Hypromellose 7.47mg

[0067] Sucrose 17.54mg

[0068] Talc, 500 mesh 31.85mg

[0069] Enteric layer

[0070] HPMCAS-LF 74.43mg

[0071] Triethyl citrate 15.14mg

[0072] Talc, 500 mesh 21.21mg

[0073] outermost layer

[0074] Coloring mixture white (HPMC+titanium dioxide) 42.79mg

[0075] HPMC 10.55mg

[0076] Talc Trace

[0077] Total 448.64mg

[0078] The preparation method is as in Example 1.

Embodiment 3

[0079] Example 3 90mg salvianolic acid A pellets / capsules

[0080] Raw material list:

[0081] Inert core

[0082] Sucrose-starch small sugar pills, 30-35 mesh 136.45mg

[0083] Salvianolic acid layer A

[0084] Salvianolic acid A 99.12mg

[0085] Sucrose 25.71mg

[0086] Hypromellose 12.91mg

[0087] separation layer

[0088] Hypromellose 9.44mg

[0089] Sucrose 27.57mg

[0090] Talc, 500 mesh 0.29mg

[0091] outermost layer

[0092] Coloring mixture white (HPMC+titanium dioxide) 33.81mg

[0093] HPMC 8.59mg

[0094] Talc Trace

[0095] Total 403.89mg

[0096] Add salvianolic acid A in the adhesive solution that contains sucrose and hydroxypropyl methylcellulose (HPMC), form sucrose content and be 6.4% (weight), HPMC content be 3.2% (weight) and salvianolic acid A content are 25% by weight suspension. The suspension was milled by a Coball Mill MS-12 to reduce the particle size of the drug. The milled suspension was coated onto 1.5 ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

A micropill of danshinolic acid A for relaxating the smooth muscle of aorta, improving the left ventricular function and the cardiac pump function, and preventing and treating myocardial ischemia is prepared from danshinolic acid A or its pharmacologically acceptable salt and one or more medicinal auxiliaries. A capsule containing said micropills is also disclosed.

Description

technical field [0001] The invention relates to salvianolic acid A pellets and salvianolic acid A capsules, in particular to pellets and capsules containing high-purity salvianolic acid A, and belongs to the technical field of medicine. Background technique [0002] Salvia miltiorrhiza is one of the drugs commonly used in traditional medicine in my country, and has a long history of clinical application. The chemical composition of Danshen is mainly divided into two parts: water-soluble components and fat-soluble components. In the early 20th century, fat-soluble components were mainly studied; since the 1980s, Chinese pharmaceutical researchers began to study water-soluble components, and dozens of water-soluble components were discovered in succession, and their chemical structures were clarified, which proved that the main water-soluble active components of Danshen Phenolic acid compounds. [0003] Salvianolic acid A is a phenolic acid component isolated from Salvia mil...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/216A61K9/16A61P9/10
Inventor 林荣倩
Owner 正宇(香港)国际有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap